Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

An Important Reminder from Vir Biotechnology

May 19, 2022 0

Vir Biotechnology Vir Biotechnology (VIR) is a commercial-stage immunology firm focused on combining immunologic insights with cutting-edge …

Exelixis First Quarter 2022 Financial Results. See Also: Milestones in Clinical and Pipeline Development

May 19, 2022 0

Exelixis Press Release This press release covers a large part of Exelixis accomplishments, including important details …

Bear Market. Bad Market. Unpredictable Market.

May 17, 2022 0

Prohost Comprehensive Letter #450 BEAR MARKET. BAD MARKET. UNPREDICTABLE MARKET. Stock market investors usually learn from …

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer’s DIisease

May 10, 2022 0

Eisai and Biogen Inc: Lecanemab Eisai and Biogen Inc. (BIIB) announced that Eisai has completed the rolling …

Positive News for Two Undervalued Firms in the Prohost Portfolio

May 5, 2022 0

Exelixis CABOMETYX Approval Exelixis (EXEL) partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a …

Vertex Provided Successful Results of VX-880 for Type 1 Diabetes Then Placed the Product on Clinical Hold

May 2, 2022 0

A lot is happening while the Stock Market is tanking and is finally being considered a …

Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings

April 27, 2022 0

Amgen Repatha Studies Repatha is the Longest Studied PCSK9i Amgen (AMGN) announced top-line results from two …

Gilead Sciences: Remdesivir is the First and Only Approved Treatment for Pediatric Patients with COVID-19. See Also: Cassava Sciences

April 26, 2022 0

Gilead Sciences Receives sNDA from the FDA for Remdesivir for Pediatric Patients with COVID-19 Gilead Sciences …

Interesting News from PTC Therapeutics and Arcturus Therapeutics Holdings

April 20, 2022 0

Arcturus Therapeutics Holdings News Arcturus Therapeutics Holdings (ARCT) shared topline data from an ongoing Phase 1/2/3 …

Gilead Sciences: The FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies. See Also: BioNTech

April 13, 2022 0

FDA Lifts Partial Clinical Hold on Gilead Sciences Studies of Magrolimab On April 12, 2022, Gilead …

What’s Going on with the Clinical-Stage Biotech Firms. See Also: Promising News From Evotec SE

April 9, 2022 0

The Clinical Stage Biotech Firms We have reasons to believe that some clinical-stage biotechnology firms, …

Promising Agreement Between Jazz Pharmaceuticals and Werewolf Therapeutics

April 8, 2022 0

Jazz Pharmaceuticals and Werewolf Therapeutics Agreement Jazz Pharmaceuticals (JAZZ) and Werewolf Therapeutics (HOWL)

Sunshine Biopharma’s New mRNA Therapeutics Killed Cancer Cells with Little or No Adverse Effects

April 5, 2022 0

Sunshine Biopharma mRNA Therapeutics Effective at Destroying Cancer Cells Sunshine Biopharma, Inc. (SBFM) – a pharmaceutical …

Gilead Sciences: The FDA Approved Yescarta® – The First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory LBCL

April 4, 2022 0

Gilead Sciences' Product Yescarta Kite - a Gilead Sciences (GILD) Company, announced the U.S. FDA has approved …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

An Important Reminder from Vir Biotechnology

Exelixis First Quarter 2022 Financial Results. See Also: Milestones in Clinical and Pipeline Development

Bear Market. Bad Market. Unpredictable Market.

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer’s DIisease

Positive News for Two Undervalued Firms in the Prohost Portfolio

Vertex Provided Successful Results of VX-880 for Type 1 Diabetes Then Placed the Product on Clinical Hold

Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings

Gilead Sciences: Remdesivir is the First and Only Approved Treatment for Pediatric Patients with COVID-19. See Also: Cassava Sciences

Interesting News from PTC Therapeutics and Arcturus Therapeutics Holdings

Gilead Sciences: The FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies. See Also: BioNTech

What’s Going on with the Clinical-Stage Biotech Firms. See Also: Promising News From Evotec SE

Promising Agreement Between Jazz Pharmaceuticals and Werewolf Therapeutics

Sunshine Biopharma’s New mRNA Therapeutics Killed Cancer Cells with Little or No Adverse Effects

Gilead Sciences: The FDA Approved Yescarta® – The First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory LBCL

Reata Pharmaceuticals Completed Rolling NDA Submission of Omaveloxolone for Friedreich’s Ataxia

News From Vertex and Cassava: Two Prohost Portfolio Selected Biotech Firms

Our Most Pressing Need. See Also: Important, Recent News from Incyte & Eli Lilly and Halozyme

Comprehensive Prohost Letter #449 – Reality

What Happened Over the Past Two Days and Biotech

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office Decision